CASE STUDY
Low-risk organ-confined prostate cancer

The CyberKnife Centre
81 Harley Street
London W1G 8PP
Tel: 020 7034 8588
cyberknifecentrelondon.co.uk
Case History
This 70-year-old male with a history of atrial fibrillation, hypertension and benign prostatic hyperplasia (BPH) presented with elevated prostate specific antigen (PSA) of 4.5 ng/ml in January 2005. He had been followed by his urologist for the previous six years with regular PSA monitoring. He had no family history of prostate cancer and underwent a TURP 2 years prior for BPH. His atrial fibrillation and hypertension were managed by Coumadin, Toprol, Lexapro and Zostenic.

The patient’s symptoms included nocturia two times and a history of erectile dysfunction. Patient denies a history of dysuria, hematuria, urinary incontinence, urinary urgency, urinary frequency or hematuria. Transrectal ultrasound (TRUS) guided biopsy revealed adenocarcinoma of the prostate in 6 of 12 biopsy cores, all of which were less than 5% positive and a Gleason score of 3 + 3. Tumor was found in both lobes of the prostate, and was staged cT1b by digital rectal examination. A CT scan of the abdomen/pelvis was unremarkable and a bone scan was negative for metastatic disease.

CyberKnife® Treatment Rationale
The patient was evaluated by Urology and Radiation Oncology for his prostate cancer. Treatment options included surgery, external beam radiation therapy (SBRT), conformal and CyberKnife monotherapy. The patient wanted a less invasive and convenient therapy in order to continue his work and day to day activities and therefore elected for CyberKnife monotherapy.

Current literature suggests that prostate cancer will respond favorably to hypofractionated radiotherapy due to the low ratio of prostate cancer. Several groups have demonstrated that hypofractionation schemes for prostate cancer achieve excellent local control with minimal toxicity to the urethra and rectum. CyberKnife stereotactic radiosurgery has been shown to decrease prostate tumor volume and decrease PSA levels of human prostate cancer cells in a mouse model. Initial studies of CyberKnife monotherapy have shown beneficial effects, including decreased PSA results and minimal or no toxicities in patients with organ-confined prostate cancer.

Treatment Planning Process
In March 2005, four fiducial markers were placed under intravenous conscious sedation in the prostate by the urologist using a TRUS-guided template. A CT scan was negative for metastatic disease. A CT scan was performed with the patient in the treatment position using a custom immobilization device. The fiducial locations were identified and the prostate and critical structures (rectum, bladder, and urethra) were contoured. The planning target volume (PTV) included the prostate with a 5-mm margin in all directions except for a smaller 3-mm posterior margin to decrease dosage to the rectum. Treatment planning was designed to encompass 95% of the target volume and minimize dose to critical structures.

Treatment Details
Tumor Volume: 29.5 cc
Imaging Technique(s): CT
Rx Dose & Isodose: 35 Gy to 82%
Conformity Index: 1.39
Tumor Coverage: 95%
Number of Beams: 130

Treatment Delivery
The patient began treatment in April 2005. A prescription dose of 35 Gy was delivered in 5 fractions over 5 consecutive days to the 82% isodose line. Two collimator sizes were used and a conformity index of 1.39 was achieved. There were 130 beams from 111 nodes delivered in an average of 43 minutes. Following the fourth treatment, the patient experienced nocturia and was given 5.4 mg Flomax for resolution of symptoms. The patient reported mild urinary frequency and mild urgency 5 days after completion of last fraction of radiosurgery and was treated with Pyridium with resolution of symptoms. Overall, the patient tolerated the treatment well.

Outcome and Follow-Up
• The patient responded to CyberKnife® treatment with a decrease in PSA value from 4.5 ng/ml to 1.3 ng/ml at one month following radiosurgery and to 0.2 ng/ml at 8 months. At 1 year following treatment, PSA remains stable at 0.2 ng/ml.
• The patient experienced mild acute urinary toxicities which resolved with medication.
• There were no reported acute rectal toxicities.
• At 1-year follow-up, there were no chronic urinary or rectal toxicities.

Conclusion and CyberKnife® Advantages
• CyberKnife monotherapy produced an early and stable reduction in PSA in a patient with low-risk organ-confined prostate cancer with minimal acute urinary toxicities and no noted chronic toxicities to date.
• CyberKnife treatment provides a convenient, minimally invasive option for patients with early-stage, organ-confined prostate cancer.

Demographics
Sex: Male
Age: 70 years
Histology: Prostate Adenocarcinoma: stage T1c

Clinical History
Referred by: Urologist
Previous Treatment: Transrectal resection of the prostate (TURP) for benign prostatic hyperplasia (BPH)

References